A Phase 3 interventional study of Cabazitaxel (XRP6258) and Docetaxel (XRP6976) in Prostate Cancer, sponsored by Sanofi. Completed at 167 sites in 25 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-05.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 5 that started in 2011, is one of 7 in phase 3, and was the 3rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Case Comprehensive Cancer Center · Sites in United States
Ages 19+
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Fundacion Oncosur · Sites in Spain
Ages 18+ · Men only
Jina Pharmaceuticals Inc.
Ages 18+ · Men only
By country, each count listing its studies:
cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,168 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 60 across the 46 interventional studies. Of the 29 that completed or were terminated, 14 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 46 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
34 studies in Prostatic Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 3rd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2011, is one of 10 in phase 3, and was the 23rd registered.
Sanofi’s Prostatic Neoplasms studies by the year they started, since 2001.
2 of the studies testing cabazitaxel in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06890832Jina Pharmaceuticals Inc.A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | 2026-12 |
| NCT06085729M.D. Anderson Cancer CenterPhase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | 2027-09-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, from their registry updates:
Among Sanofi’s 34 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
To compare efficacy of cabazitaxel at 20 mg/m\^2 and 25 mg/m\^2 to docetaxel for:
Participants were treated until progressive disease, unacceptable toxicity, or participant's refusal of further study treatment. All participants were followed when on study treatment and after completion of study treatment during follow up period until death or the study cutoff date, whichever comes first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabazitaxel 25 mg/m\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.
Drug: Cabazitaxel (XRP6258) · Drug: Prednisone
Cabazitaxel 20 mg/m\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
Drug: Cabazitaxel (XRP6258) · Drug: Prednisone
Docetaxel (TXT) 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
Drug: Docetaxel (XRP6976) · Drug: Prednisone
Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
Pharmaceutical form: Tablet; Route of administration: Oral
Overall Survival (OS)
OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant's last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.
Time frame: Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months )
Progression Free Survival (PFS)
PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.
Time frame: Baseline up to tumor progression, PSA progression, pain progression or death (maximum duration: 51 months)
Time to Tumor Progression Free Survival
Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.
Time frame: Baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Percentage of Participants With Overall Objective Tumor Response
Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS)
Time to PSA-PFS: time interval between date of randomization \& first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(≥50% decline from baseline PSA of ≥10 ng/mL):increase of ≥25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved ≥50% decline from baseline PSA ≥10 ng/mL):increase of ≥25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA \<10 ng/mL):(a)in participants with baseline PSA\>0 ng/mL\&\<10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value ≥2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.
Time frame: Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Percentage of Participants With PSA Response
PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.
Time frame: Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Time to Pain Progression Free Survival (Pain PFS)
Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of ≥1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.
Time frame: Baseline until disease progression, death or study cut-off date (maximum duration: 51 months)
Percentage of Participants With Pain Response
Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in analgesic score, or a ≥50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score≥10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.
Time frame: Baseline until pain progression, death or study cut-off date (maximum duration: 51 months)
Skeletal Related Events (SRE) Free Survival
SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.
Time frame: Baseline until occurrence of first SRE or death (maximum duration: 51 months)
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)
FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.
Time frame: Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL
FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.
Time frame: Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)
The study was conducted at 159 centers in 25 countries. A total of 1510 participants were screened between 17 May 2011 and 09 September 2015 of whom 1168 participants were randomized and 342 were considered as screen failures.
| Milestone | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Started | 391 | 389 | 388 |
| Treated | 388 | 382 | 377 |
| Completed | 389 | 385 | 384 |
| Not completed | 2 | 4 | 4 |
| Withdrew: Lost to follow-up | 2 | 4 | 4 |
OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant's last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.
| months | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Overall Survival (OS) | 24.3 (22.18 to 27.60) | 24.5 (21.75 to 27.20) | 25.2 (22.90 to 26.97) |
PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.
| months | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Progression Free Survival (PFS) | 5.3 (4.86 to 5.78) | 4.4 (3.91 to 5.09) | 5.1 (4.60 to 5.72) |
Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.
| months | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Time to Tumor Progression Free Survival | 12.1 (11.30 to 13.77) | 13.4 (11.37 to 14.75) | 13.1 (11.66 to 14.32) |
Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Percentage of Participants With Overall Objective Tumor Response | 30.9 (24.0 to 37.7) | 32.4 (25.8 to 39.1) | 41.6 (34.3 to 49.0) |
Time to PSA-PFS: time interval between date of randomization \& first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(≥50% decline from baseline PSA of ≥10 ng/mL):increase of ≥25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved ≥50% decline from baseline PSA ≥10 ng/mL):increase of ≥25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA \<10 ng/mL):(a)in participants with baseline PSA\>0 ng/mL\&\<10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value ≥2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.
| months | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS) | 8.3 (7.66 to 9.20) | 8.2 (7.43 to 8.90) | 9.2 (8.44 to 9.92) |
PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.
| percentage of participants | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Percentage of Participants With PSA Response | 68.4 (63.5 to 73.2) | 60.7 (55.5 to 65.8) | 68.7 (63.8 to 73.6) |
Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of ≥1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.
| months | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Time to Pain Progression Free Survival (Pain PFS) | 10.1 (8.28 to 11.76) | 8.0 (6.90 to 9.66) | 7.3 (6.44 to 9.30) |
Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in analgesic score, or a ≥50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score≥10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.
| percentage of participants | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Percentage of Participants With Pain Response | 40.7 (30.0 to 51.4) | 42.4 (32.7 to 52.2) | 39.4 (30.0 to 48.8) |
SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.
| months | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Skeletal Related Events (SRE) Free Survival | 19.0 (15.24 to 22.44) | 19.2 (15.21 to 24.61) | 17.1 (14.59 to 20.50) |
FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.
| units on a scale | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Change at Cycle 1 | 4.17 (1.3 to 7.05) | 7.66 (4.79 to 10.53) | 6.93 (3.97 to 9.88) |
| Change at Cycle 2 | 5.33 (2.46 to 8.2) | 7.15 (4.28 to 10.01) | 5.28 (2.32 to 8.24) |
| Change at Cycle 3 | 4.94 (2.06 to 7.82) | 6.79 (3.93 to 9.66) | 4.61 (1.64 to 7.58) |
| Change at Cycle 4 | 4.07 (1.17 to 6.96) | 5.22 (2.35 to 8.09) | 4.01 (1.03 to 6.99) |
| Change at Cycle 5 | 4.36 (1.44 to 7.27) | 5.16 (2.26 to 8.06) | 4.09 (1.09 to 7.08) |
| Change at Cycle 6 | 3.46 (0.53 to 6.39) | 3.8 (0.88 to 6.73) | 3.37 (0.35 to 6.39) |
| Change at Cycle 7 | 3.16 (0.2 to 6.12) | 3.66 (0.71 to 6.61) | 3.42 (0.38 to 6.45) |
| Change at Cycle 8 | 2.61 (-0.37 to 5.59) | 2.71 (-0.27 to 5.68) | 1.67 (-1.39 to 4.73) |
| Change at Cycle 9 | 2.2 (-0.87 to 5.27) | 2.67 (-0.35 to 5.68) | 1.89 (-1.22 to 5.01) |
| Change at Cycle 10 | 2.08 (-1.05 to 5.21) | 2.09 (-0.99 to 5.18) | 1.84 (-1.32 to 5) |
| Change at Cycle 11 | 0.15 (-3.18 to 3.47) | 3.35 (0.1 to 6.6) | 2.68 (-0.67 to 6.02) |
| Change at Cycle 12 | 0.52 (-2.94 to 3.97) | 3.95 (0.61 to 7.29) | 0.63 (-2.78 to 4.05) |
| Change at Cycle 13 | 1.79 (-1.94 to 5.53) | 2.48 (-0.95 to 5.91) | 0.55 (-3 to 4.09) |
| Change at Cycle 14 | -1.78 (-5.56 to 2) | 2.2 (-1.29 to 5.69) | -0.42 (-4.06 to 3.21) |
| Change at Cycle 15 | -3.49 (-7.5 to 0.51) | 1.74 (-1.82 to 5.3) | 1.22 (-2.51 to 4.95) |
| Change at Cycle 16 | -3.83 (-7.89 to 0.23) | 1.62 (-2.11 to 5.35) | 0.5 (-3.3 to 4.3) |
| Change at Follow-up 1 | -1.08 (-4.15 to 1.99) | -1.45 (-4.48 to 1.59) | -1.82 (-4.97 to 1.32) |
| Change at Follow-up 2 | -0.02 (-3.16 to 3.13) | -1.98 (-5.17 to 1.21) | -1.78 (-5.04 to 1.47) |
| Change at Follow-up 3 | -0.55 (-3.83 to 2.74) | -2.16 (-5.47 to 1.14) | -2.68 (-6.08 to 0.72) |
| Change at Follow-up 4 | -1.19 (-4.61 to 2.23) | -3.64 (-7.18 to -0.1) | -1.7 (-5.25 to 1.84) |
| Change at Follow-up 5 | -2.05 (-5.61 to 1.51) | -6.73 (-10.39 to -3.06) | -0.6 (-4.18 to 2.99) |
| Change at Follow-up 6 | -1.17 (-4.92 to 2.58) | -5.36 (-9.32 to -1.4) | -4.05 (-7.87 to -0.23) |
FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.
| units on a scale | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Change at Cycle 1 | 3.31 (1.05 to 5.58) | 6.09 (3.83 to 8.35) | 5.76 (3.43 to 8.09) |
| Change at Cycle 2 | 4.37 (2.1 to 6.64) | 5.96 (3.7 to 8.21) | 4.26 (1.92 to 6.59) |
| Change at Cycle 3 | 4.31 (2.04 to 6.58) | 5.28 (3.02 to 7.53) | 3.65 (1.31 to 5.99) |
| Change at Cycle 4 | 3.39 (1.11 to 5.67) | 4.1 (1.83 to 6.36) | 3.2 (0.85 to 5.55) |
| Change at Cycle 5 | 3.41 (1.11 to 5.7) | 4.05 (1.76 to 6.34) | 3.1 (0.74 to 5.46) |
| Change at Cycle 6 | 2.76 (0.45 to 5.07) | 3.15 (0.85 to 5.46) | 2.88 (0.5 to 5.26) |
| Change at Cycle 7 | 2.29 (-0.05 to 4.62) | 3.14 (0.81 to 5.47) | 2.94 (0.54 to 5.34) |
| Change at Cycle 8 | 1.67 (-0.69 to 4.02) | 2.26 (-0.09 to 4.61) | 1.49 (-0.92 to 3.91) |
| Change at Cycle 9 | 1.75 (-0.67 to 4.18) | 2.15 (-0.24 to 4.53) | 1.73 (-0.73 to 4.19) |
| Change at Cycle 10 | 1.52 (-0.96 to 4) | 1.56 (-0.88 to 3.99) | 1.62 (-0.89 to 4.12) |
| Change at Cycle 11 | 0.35 (-2.29 to 3) | 2.72 (0.15 to 5.3) | 2.19 (-0.46 to 4.84) |
| Change at Cycle 12 | 1.04 (-1.7 to 3.79) | 3.08 (0.43 to 5.73) | 0.75 (-1.95 to 3.46) |
| Change at Cycle 13 | 2.13 (-0.85 to 5.11) | 1.78 (-0.94 to 4.5) | 0.82 (-1.98 to 3.62) |
| Change at Cycle 14 | -0.13 (-3.15 to 2.89) | 1.59 (-1.18 to 4.36) | -0.07 (-2.95 to 2.81) |
| Change at Cycle 15 | -2.1 (-5.29 to 1.09) | 1.29 (-1.53 to 4.11) | 1.49 (-1.47 to 4.45) |
| Change at Cycle 16 | -2.26 (-5.49 to 0.97) | 1.23 (-1.73 to 4.19) | 1.44 (-1.59 to 4.47) |
| Change at Follow-up 1 | -0.96 (-3.38 to 1.47) | -1.26 (-3.66 to 1.14) | -1.62 (-4.11 to 0.86) |
| Change at Follow-up 2 | -0.07 (-2.56 to 2.42) | -1.12 (-3.65 to 1.41) | -1.05 (-3.62 to 1.53) |
| Change at Follow-up 3 | -0.32 (-2.92 to 2.28) | -1.67 (-4.29 to 0.96) | -1.98 (-4.68 to 0.72) |
| Change at Follow-up 4 | -0.91 (-3.62 to 1.8) | -2.54 (-5.36 to 0.29) | -1.03 (-3.84 to 1.78) |
| Change at Follow-up 5 | -2.15 (-4.99 to 0.69) | -5.36 (-8.27 to -2.44) | -0.82 (-3.67 to 2.02) |
| Change at Follow-up 6 | -1.77 (-4.75 to 1.2) | -5.32 (-8.49 to -2.16) | -2.76 (-5.82 to 0.3) |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (up to 83 months) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel 75 mg/m^2 | — | 126/387 (32.6%) | 353/387 (91.2%) |
| Cabazitaxel 20 mg/m^2 | — | 127/369 (34.4%) | 323/369 (87.5%) |
| Cabazitaxel 25 mg/m^2 | — | 188/391 (48.1%) | 354/391 (90.5%) |
| Event | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 27/387 | 7/369 | 40/391 |
| Neutropenic infectionInfections and infestations | 12/387 | 3/369 | 21/391 |
| HaematuriaRenal and urinary disorders | 2/387 | 10/369 | 13/391 |
| PneumoniaInfections and infestations | 8/387 | 3/369 | 12/391 |
| NeutropeniaBlood and lymphatic system disorders | 4/387 | 4/369 | 10/391 |
| DiarrhoeaGastrointestinal disorders | 4/387 | 2/369 | 10/391 |
| Urinary tract infectionInfections and infestations | 2/387 | 9/369 | 8/391 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/387 | 8/369 | 9/391 |
| AnaemiaBlood and lymphatic system disorders | 2/387 | 8/369 | 5/391 |
| Urinary tract obstructionRenal and urinary disorders | 1/387 | 6/369 | 3/391 |
| Event | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 140/387 | 120/369 | 190/391 |
| AlopeciaSkin and subcutaneous tissue disorders | 151/387 | 33/369 | 51/391 |
| FatigueGeneral disorders | 110/387 | 105/369 | 126/391 |
| NauseaGastrointestinal disorders | 86/387 | 92/369 | 125/391 |
| Peripheral sensory neuropathyNervous system disorders | 97/387 | 43/369 | 48/391 |
| ConstipationGastrointestinal disorders | 69/387 | 90/369 | 78/391 |
| AstheniaGeneral disorders | 94/387 | 84/369 | 90/391 |
| HaematuriaRenal and urinary disorders | 13/387 | 69/369 | 91/391 |
| Oedema peripheralGeneral disorders | 78/387 | 36/369 | 30/391 |
| VomitingGastrointestinal disorders | 44/387 | 44/369 | 75/391 |
| Age, Customized(Participants) | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 | Total |
|---|---|---|---|---|
| <65 years | 123 | 128 | 125 | 376 |
| 65-74 years | 181 | 187 | 182 | 550 |
| ≥75 years | 87 | 74 | 81 | 242 |
| Sex: Female, Male(Participants) | Docetaxel 75 mg/m^2 | Cabazitaxel 20 mg/m^2 | Cabazitaxel 25 mg/m^2 | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 391 | 389 | 388 | 1168 |
Showing the first 100 of 167 sites across 25 countries. Choose a country and city above to see the rest.
Ran from May 2011 to primary completion in Sep 2015, 52 months.
Results were first posted in Mar 2017, 1 year 6 months after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 52 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabazitaxel